Sirolimus for the treatment of children with various complicated vascular anomalies

European Journal of Pediatrics

Volumn 174, Issue 12, 2015, Pages 1579-1584

  Lackner, Herwig ^a   Karastaneva, Anna ^a   Schwinger, Wolfgang ^a   Benesch, Martin ^a   Sovinz, Petra ^a   Seidel, Markus ^a   Sperl, Daniela ^a   Lanz, Sofia ^a   Haxhija, Emir ^a   Reiterer, Friedrich ^a   Sorantin, Erich ^a   Urban, Christian E ^a  

^a MEDICAL UNIVERSITY OF GRAZ   (Austria)

Author keywords

Children; Sirolimus; Treatment; Vascular anomalies

Indexed keywords

RAPAMYCIN; ANGIOGENESIS INHIBITOR;

ARTICLE; CHILD; CLINICAL ARTICLE; COMPUTER ASSISTED TOMOGRAPHY; CONGENITAL BLOOD VESSEL MALFORMATION; DRUG EFFICACY; DRUG TOLERABILITY; FEMALE; HEMANGIOENDOTHELIOMA; HUMAN; INFANT; INFECTION; KAPOSIFORM HEMANGIOENDOTHELIOMA; KASABACH MERRITT SYNDROME; LEUKOPENIA; LYMPHATICOVENOUS MALFORMATION; MALE; NEWBORN; NUCLEAR MAGNETIC RESONANCE IMAGING; ORBITAL LYMPHATIC MALFORMATION; PRIORITY JOURNAL; PULMONARY LYMPHANGIECTASIA; REMISSION; RETROSPECTIVE STUDY; TREATMENT DURATION; TREATMENT OUTCOME; TREATMENT RESPONSE; VASCULAR TUMOR; VASCULAR MALFORMATIONS;

ANGIOGENESIS INHIBITORS; FEMALE; HUMANS; INFANT; INFANT, NEWBORN; MALE; RETROSPECTIVE STUDIES; SIROLIMUS; TOMOGRAPHY, X-RAY COMPUTED; TREATMENT OUTCOME; VASCULAR MALFORMATIONS;

EID: 84948568918     PISSN: 03406199     EISSN: 14321076     Source Type: Journal    
DOI: 10.1007/s00431-015-2572-y     Document Type: Article

References (30)

1. Adams DM, Wentzel MS (2008) The role of the hematologist/oncologist in the care of patients with vascular anomalies. Pediatr Clin N Am 55:339–355
2. Blatt J, Stavas J, Moats-Staats B et al (2010) Treatment of childhood kaposiform hemangioendothelioma with sirolimus. Pediatr Blood Cancer 55:1396–1398
3. Blei F (2015) Kaposiform hemangioendothelioma: therapeutic efficacy for an enigmatic diagnosis. Pediatr Blood Cancer 62:551–552
4. Blei F (2012) Medical management of vascular anomalies. Facial Plast Surg 28:575–583
5. Ezekowitz RA, Mulliken JB, Folkman J (1992) Interferon alfa-2a therapy for life-threatening hemangiomas of infancy. N Engl J Med 326:1456–1463
6. Fahrtash F, McCahon E, Arbuckle S (2010) Successful treatment of kaposiform hemangioendothelioma and tufted angioma with vincristine. J Pediatr Hematol Oncol 32:506–510
7. Falger JC, Mueller T, Arbeiter K et al (2006) Conversion from calcineurin inhibitor to sirolimus in pediatric chronic allograft nephropathy. Pediatr Transplant 10:565–569
8. Fost NC, Esterly NB (1968) Successful treatment of juvenile hemangiomas with prednisone. J Pediatr 72:351–357
9. Garzon MC, Huang JT, Enjolras O et al (2007) Vascular malformations: part I. J Am Acad Dermatol 56:353–370
10. Hammill AM, Wentzel MS, Gupta A et al (2011) Sirolimus for the treatment of complicated vascular anomalies in children. Pediatr Blood Cancer 57:1018–1024
11. Holmes WJ, Mishra A, Gorst C et al (2011) Propranolol as first-line treatment for rapidly proliferating infantile haemangiomas. J Plast Reconstr Aesthet Surg 64:445–451
12. ISSVA Classification of Vascular Anomalies ©(2014) International Society for the Study of Vascular Anomalies. Available at “issva.org/classification”. Accessed April 2014
13. Jahnel J, Lackner H, Reiterer F et al (2012) Kaposiform hemangioendothelioma with Kasabach. Merritt phenomenon: from vincristine to sirolimus. Klin Padiatr 224:395–397
14. Kai L, Wang Z, Yao W et al (2014) Sirolimus, a promising treatment for refractory Kaposiform hemangioendothelioma. J Cancer Res Clin Oncol 140:471–476
15. Kim D, Benjamin L, Wysong A et al (2015) Treatment of complex periorbital venolymphatic malformation in a neonate with a combination therapy of sirolimus and prednisolone. Dermatol Ther Mar 5 (Epub ahead of print)
16. Lackner H, Urban C, Schwinger W et al (1995) Cyclophosphamide therapy in life-threatening inoperable cystic hygromas. Pediatr Surg Int 10:199–201
17. Leaute-Labreze C, Dumas de la Roque E, Hubiche T et al (2008) Propranolol for severe hemangiomas of infancy. N Engl J Med 358:2649–2651
18. Margolin JF, Soni HM, Pimpalwar S (2014) Medical therapy for pediatric vascular anomalies. Semin Plast Surg 28:79–86
19. Pan WK, Li P, Huang Q (2015) Propranolol induces regression of hemangioma cells via the down-regulation of the PI3K/Akt/eNOS/VEGF pathway. Pediatr Blood Cancer. doi:10.1002/pbc.25453
20. Reinglas J, Ramphal R, Bromwich M (2011) The successful management of diffuse lymphangiomatosis using sirolimus: a case report. Laryngoscope 121:1851–1854
21. Sadan N, Wolach B (1996) Treatment of hemangiomas of infants with high doses of prednisone. J Pediatr 128:141–146
22. Sans V, de la Roque ED, Berge J et al (2009) Propranolol for severe infantile hemangiomas: follow-up report. Pediatrics 124:423–431
23. Schroeder U, Lauten M, Stichtenoth G et al (2014) Laryngomalacia and complicated, life-threatening mTOR-positive Kaposiform hemangioendothelioma cured by Supraglottoplasty and sirolimus. Klin Padiatr 226:362–368
24. Timke C, Krause MF, Oppermann HC et al (2007) Interferon alpha 2b treatment in an eleven-year-old boy with disseminated lymphangiomatosis. Pediatr Blood Cancer 48:108–111
25. Trenor CC (2011) Sirolimus for refractory vascular anomalies. Pediatr Blood Cancer 57:904–905
26. Uno T, Ito S, Nakazawa A et al (2015) Successful treatment of Kaposiform hemangioendothelioma with everolimus. Pediatr Blood Cancer 62:536–538
27. Vesikari T, Nuutila A, Cantell K (1988) Neurologic sequelae following interferon therapy of juvenile laryngeal papilloma. Acta Paediatr Scand 77:619–622
28. Wang Z, Li K, Dong K et al (2013) Successful treatment of Kasabach-Merritt phenomenon arising from Kaposiform hemangioendothelioma by sirolimus. J Pediatr Hematol Oncol 37:72–73
29. White CW, Wolf SJ, Korones DN et al (1991) Treatment of childhood angiomatous diseases with recombinant interferon alfa-2a. J Pediatr 118:59–66
30. Zarem HA, Edgerton MT (1967) Induced resolution of cavernous hemangiomas following prednisolone therapy. Plast Reconstr Surg 39:76–83